A trial listing for mazdutide was updated on August 17, 2026. The study, titled "Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial," is registered under identifier NCT07767552.
The trial's current status is listed as not yet recruiting, meaning enrollment has not begun. The listing does not specify a phase, with the phase field marked as not applicable.
According to the registration, the trial is designed as a multicentre, double blind, randomised, and placebo controlled study. It focuses on evaluating mazdutide in relation to remission of type 2 diabetes, as stated in the trial title. No results, timelines, or additional design details are included in this update.
Mazdutide remains classified as an unapproved compound under research investigation. This trial update reflects only the registration status as of the date noted and does not indicate any outcomes, safety findings, or efficacy data. No dosing information or other trial specifics were provided in the available record.
Readers interested in learning more about mazdutide can consult the compound overview for additional background and context.